JP2004525602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525602A5 JP2004525602A5 JP2001577507A JP2001577507A JP2004525602A5 JP 2004525602 A5 JP2004525602 A5 JP 2004525602A5 JP 2001577507 A JP2001577507 A JP 2001577507A JP 2001577507 A JP2001577507 A JP 2001577507A JP 2004525602 A5 JP2004525602 A5 JP 2004525602A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- pharmaceutical composition
- composition according
- purified preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims 23
- 150000007523 nucleic acids Chemical class 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 241001631646 Papillomaviridae Species 0.000 claims 5
- 108020004999 Messenger RNA Proteins 0.000 claims 4
- 229920002106 messenger RNA Polymers 0.000 claims 4
- 210000000981 Epithelium Anatomy 0.000 claims 3
- 241000700721 Hepatitis B virus Species 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 230000000699 topical Effects 0.000 claims 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 2
- 108010091307 Catalytic DNA Proteins 0.000 claims 2
- 101700080605 NUC1 Proteins 0.000 claims 2
- 229920000272 Oligonucleotide Polymers 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 230000004059 degradation Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 210000002919 epithelial cells Anatomy 0.000 claims 2
- 101700006494 nucA Proteins 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 230000004962 physiological condition Effects 0.000 claims 2
- 229920002033 ribozyme Polymers 0.000 claims 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 1
- 206010008263 Cervical dysplasia Diseases 0.000 claims 1
- 210000003679 Cervix Uteri Anatomy 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010061809 Cervix carcinoma stage 0 Diseases 0.000 claims 1
- 229920001405 Coding region Polymers 0.000 claims 1
- 210000002615 Epidermis Anatomy 0.000 claims 1
- 208000006454 Hepatitis Diseases 0.000 claims 1
- 206010023849 Laryngeal papilloma Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 210000003802 Sputum Anatomy 0.000 claims 1
- 102000016350 Viral Proteins Human genes 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 230000001085 cytostatic Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001402 polyadenylating Effects 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 230000001131 transforming Effects 0.000 claims 1
- 230000003612 virological Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54844900A | 2000-04-13 | 2000-04-13 | |
| US25181000P | 2000-12-07 | 2000-12-07 | |
| PCT/US2001/012130 WO2001079524A2 (fr) | 2000-04-13 | 2001-04-13 | Agents toxiques, riboyzmes, andyzmes et oligonulceotides antisens specifiques des tissus et des pathogenes et procede d'utilisation associe |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004525602A JP2004525602A (ja) | 2004-08-26 |
| JP2004525602A5 true JP2004525602A5 (fr) | 2005-11-17 |
Family
ID=26941841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001577507A Pending JP2004525602A (ja) | 2000-04-13 | 2001-04-13 | 組織特異的および病原菌特異的毒性剤、リボザイム、ＤＮＡｚｙｍｅおよびアンチセンスオリゴヌクレオチドとそれらの使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1397489A4 (fr) |
| JP (1) | JP2004525602A (fr) |
| AU (2) | AU5347101A (fr) |
| CA (1) | CA2406403A1 (fr) |
| WO (1) | WO2001079524A2 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004113498A2 (fr) * | 2003-06-13 | 2004-12-29 | University Of Medicine And Dentistry Of New Jersey | Arn interferases et leurs procedes d'utilisation |
| EP1677834B1 (fr) * | 2003-10-06 | 2014-01-08 | Gangagen, Inc. | Phage therapeutique dose de maniere definie |
| SG11201604198YA (en) | 2013-12-30 | 2016-07-28 | Curevac Ag | Methods for rna analysis |
| US20210022324A1 (en) * | 2018-03-05 | 2021-01-28 | Dr. Reddy's Institute Of Life Sciences | Embryonic zebrafish models using dnazyme mediated knockdown |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69033850T2 (de) * | 1989-12-01 | 2002-06-06 | Vysis Inc | Nukleinsäuresonden zum Nachweis von HPV-Transkripts |
| GB9015845D0 (en) * | 1990-07-19 | 1990-09-05 | Emery Vincent C | Diagnostic method |
| FR2679254B1 (fr) * | 1991-07-17 | 1993-11-19 | Clonatec | Sondes oligonucleotidiques pour le typage et la detection des papillomavirus humains. |
| JPH08500481A (ja) * | 1992-05-11 | 1996-01-23 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | ウイルスの複製を阻害するための方法および薬剤 |
| US5767259A (en) * | 1994-12-27 | 1998-06-16 | Naxcor | Oligonucleotides containing base-free linking groups with photoactivatable side chains |
| WO1994026934A2 (fr) * | 1993-05-06 | 1994-11-24 | Baxter Diagnostics Inc. | Methode de detection du papillomavirus chez l'homme |
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US5989804A (en) * | 1994-07-08 | 1999-11-23 | New England Medical Center Hospitals, Inc. | E6 binding proteins |
| US5985662A (en) * | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
| WO2000009673A1 (fr) * | 1998-08-13 | 2000-02-24 | Johnson & Johnson Research Pty. Limited | Dnazymes et methodes de traitement de troubles en rapport avec le papillomavirus |
| AU2875602A (en) * | 2000-12-07 | 2002-06-18 | Univ Pennsylvania | Selection of catalytic nucleic acids targeted to infectious agents |
-
2001
- 2001-04-13 AU AU5347101A patent/AU5347101A/xx active Pending
- 2001-04-13 EP EP01926973A patent/EP1397489A4/fr not_active Withdrawn
- 2001-04-13 CA CA002406403A patent/CA2406403A1/fr not_active Abandoned
- 2001-04-13 JP JP2001577507A patent/JP2004525602A/ja active Pending
- 2001-04-13 AU AU2001253471A patent/AU2001253471B2/en not_active Ceased
- 2001-04-13 WO PCT/US2001/012130 patent/WO2001079524A2/fr active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Foldvari et al. | Non-viral gene therapy: Gains and challenges of non-invasive administration methods | |
| JP6715325B2 (ja) | ｓｉＲＮＡ、ｓｉＲＮＡを含む医薬組成物及び結合体、並びにそれらの応用 | |
| JP4709545B2 (ja) | 修飾された低分子干渉ｒｎａ分子および使用方法 | |
| KR102413007B1 (ko) | 짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제 | |
| JP2020525011A (ja) | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 | |
| WO1999004819A1 (fr) | Compositions de liposomes pour la distribution des catalyseurs de l'acide nucleique | |
| KR900700603A (ko) | 리보자임 | |
| WO2010135207A1 (fr) | Compositions comprenant des amphiphiles et des colipides cationiques pour administrer des molécules thérapeutiques | |
| US20040018520A1 (en) | Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein | |
| EP3268474B1 (fr) | Oligonucléotides correspondant à l'exon 73 de col7a1 pour la thérapie de l'épidermolyse bulleuse | |
| Kobayashi et al. | The hydrodynamics-based procedure for controlling the pharmacokinetics of gene medicines at whole body, organ and cellular levels | |
| Imai et al. | Strategies of gene transfer to the kidney | |
| CN115698288A (zh) | 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途 | |
| JP2004525602A5 (fr) | ||
| US7704965B2 (en) | Methods and materials for treating human papillomavirus infections | |
| WO2011130065A1 (fr) | Inhibition à médiation par arn interférence de l'expression du gène met à l'aide de petits acides nucléiques interférents (sian) | |
| US20080317717A1 (en) | Anti-hepatitis b virus ribozymal nucleic acid | |
| TW201919654A (zh) | 用於抑制α-ENaC表現之RNAi試劑及使用方法 | |
| WO2000009673A1 (fr) | Dnazymes et methodes de traitement de troubles en rapport avec le papillomavirus | |
| AU2004282998A1 (en) | DNA delivery with gemini cationic surfactants | |
| Ito et al. | Liposome-mediated gene therapy in the kidney | |
| CA2343067A1 (fr) | Molecules hybridantes en epingle a cheveux servant a moduler l'expression genique | |
| EP2031059A1 (fr) | SiDNA contre le virus de l'hépatite C (HCV) | |
| CA2797567A1 (fr) | Compositions et methodes pour reduire les cicatrices et traiter la fibrose | |
| JP2013527169A5 (fr) |